• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics Inc (NQ: FULC )

    6.310 +0.110 (+1.77%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,400,718
    Open 6.200
    Bid (Size) 5.680 (1)
    Ask (Size) 6.380 (10)
    Prev. Close 6.200
    Today's Range 5.920 - 6.345
    52wk Range 3.140 - 13.70
    Shares Outstanding 61,758,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga

    Performance

    YTD
    -12.48%
    -12.48%
    1 Month
    -22.86%
    -22.86%
    3 Month
    -32.22%
    -32.22%
    6 Month
    -12.48%
    -12.48%
    1 Year
    +94.15%
    +94.15%

    More News

    Read More
    Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
    Via Investor Brand Network
    Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
    Via Investor Brand Network
    FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics to Participate in Upcoming May Conferences
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
    Via InvestorPlace
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.